New patent for the drug Glaxo Grp BREO ELLIPTA – DrugPatentWatch
Annual Drug Patent Expiration for BREO+ELLIPTA
Breo Ellipta is a drug marketed by Glaxo Grp Ltd and included in one NDA. It is available from two suppliers. There are ten patents protecting this drug.
Trends in the price of BREO ELLIPTA drugs.
Drug patent litigation for BREO ELLIPTA.
This drug has two hundred and nine patent family members in thirty-three countries.
The generic ingredient in BREO ELLIPTA is fluticasone furoate; vilanterol triphenatate. Two registered suppliers for this compound. Additional details are available on fluticasone furoate; vilanterol trifenatate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Make Better Decisions with DrugPatentWatch
» Start Your Free Trial Today «
Copyright © DrugPatentWatch. Originally published in New patent for the drug Glaxo Grp BREO ELLIPTA
